徳島大学 教育・研究者情報データベース(EDB)

1. 中屋 豊

   役割	任意
   貢献度	任意
   学籍番号	推奨

2. 原田 永勝

   役割	任意
   貢献度	任意
   学籍番号	推奨

3. 馬渡 一諭

   役割	任意
   貢献度	任意
   学籍番号	推奨

4. 髙橋 章([徳島大学.大学院医歯薬学研究部.医学域.栄養科学部門.医科栄養学系.予防環境栄養学])

   役割	任意
   貢献度	任意
   学籍番号	推奨

5. 保坂 利男

   役割	任意
   貢献度	任意
   学籍番号	推奨

(英) Control of hypertension in metabolic syndrome

(日) メタボリック症候群における高血圧の管理

(英) Metabolic syndrome includes abdominal obesity, hyperlipidemia, diabetes, and hypertension. All, but hypertension, are obviously related to metabolism. However, hypertension might result from, at least in part, abdominal obesity, because adipose tissue produces bioactive mediators (adipocytokines)which increase blood pressure. In treatment of hypertension, we should concern insulin resistance, which is a major risk factor of cardiovascular events. Angiotensin converting enzyme inhibitor is known to improve insulin resistance, but results of angiotensin receptor blocker in animal studies are controversial. In clinical trial, there are many established data that ARBs prevent new onset of diabetes mellitus, suggesting that this agent also has a beneficial effect on glucose metabolism. Short acting Ca-antagonists, such as nifedipine, decrease insulin sensitivity, but long-acting Ca-antagonists increase it. βblockers decrease insulin sensitivity but those with α-blocking action improve insulin resistance. Recent study, ARB is more potent to reduce cardiovascular risk in those with obesity than in those with normal body weight, suggesting some drugs are more effective in metabolic syndrome. Thus, when we chose antihypertensive drugs in treating patients with metabolic syndrome, we have to choose proper drugs in addition to modify life-style.

1. 高血圧(hypertension)
2. 糖尿病(diabetes mellitus)
3. (英) metabolic syndrome
4. (英) angiotensin
5. インスリン抵抗性(insulin resistance)